ijms-logo

Journal Browser

Journal Browser

Insights into Photodynamic Therapy 2.0

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 3255

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biochemical Science and Technology, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 10617, Taiwan
Interests: photodynamic therapy; drug delivery system; cell biology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is well known that photodynamic therapy (PDT), combining photosensitizer and light irradiation, has been developed as an alternative approach for treating cancers, infections, and a range of other diseases. Over the last 40 years, there has been much progress in developing photosensitizers and related delivery systems, understanding the mechanistic mechanisms in cellular responses and their influences on the immune response, and designing clinical trials for various diseases. Recently, combining PDT and other therapies has been shown to achieve better therapeutic outcomes in disease management.

This Special Issue, “Insights into Photodynamic Therapy 2.0”, will focus on experimental papers, up-to-date review articles, and commentaries that can provide molecular insights in the fields of photodynamic therapy and photodynamic inactivation. Combined strategies of PDT and other therapies are especially, but not exclusively, welcome for this Special Issue. Authors are invited to submit manuscripts that relate to the molecular aspects of basic biology and clinical research in photodynamic therapy. The results from these articles may provide pivotal information for our understanding of PDT biology and for devising clinical strategies that may enhance the development of photodynamic medicine.

Prof. Chin-Tin Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Photodynamic therapy
  • Photodynamic inactivation
  • Cancer
  • Infections
  • Combinational therapy

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

20 pages, 4798 KiB  
Article
In Search of a Phosphorus Dendrimer-Based Carrier of Rose Bengal: Tyramine Linker Limits Fluorescent and Phototoxic Properties of a Photosensitizer
by Krzysztof Sztandera, Monika Marcinkowska, Michał Gorzkiewicz, Anna Janaszewska, Regis Laurent, Maria Zabłocka, Serge Mignani, Jean Pierre Majoral and Barbara Klajnert-Maculewicz
Int. J. Mol. Sci. 2020, 21(12), 4456; https://doi.org/10.3390/ijms21124456 - 23 Jun 2020
Cited by 13 | Viewed by 2912
Abstract
Photodynamic therapy (PDT) is a skin cancer treatment alternative to chemotherapy and radiotherapy. This method exploits three elements: a phototoxic compound (photosensitizer), light source and oxygen. Upon irradiation by light of a specific wavelength, the photosensitizer generates reactive oxygen species triggering the cascade [...] Read more.
Photodynamic therapy (PDT) is a skin cancer treatment alternative to chemotherapy and radiotherapy. This method exploits three elements: a phototoxic compound (photosensitizer), light source and oxygen. Upon irradiation by light of a specific wavelength, the photosensitizer generates reactive oxygen species triggering the cascade of reactions leading to cell death. The positive therapeutic effect of PDT may be limited due to low solubility, low tumor specificity and inefficient cellular uptake of photosensitizers. A promising approach to overcome these obstacles involves the use of nanocarrier systems. The aim of this initial study was to determine the potential of the application of phosphorus dendrimers as carriers of a photosensitizer—rose bengal (RB). The primary goal involved the synthesis and in vitro studies of covalent drug–dendrimer conjugates. Our approach allowed us to obtain RB–dendrimer conjugates with the use of tyramine as an aromatic linker between the carrier and the drug. The compounds were characterized by FT-IR, 1H NMR, 13C NMR, 31P NMR, size and zeta potential measurements and spectrofluorimetric analysis. The dialysis to check the drug release from the conjugate, flow cytometry to specify intracellular uptake, and singlet oxygen generation assay were also applied. Finally, we used MTT assay to determine the biological activity of the tested compounds. The results of our experiments indicate that the conjugation of RB to phosphorus dendrimers via the tyramine linker decreases photodynamic activity of RB. Full article
(This article belongs to the Special Issue Insights into Photodynamic Therapy 2.0)
Show Figures

Graphical abstract

Back to TopTop